InflaRx N.V.

Contributing Author

Recent Articles by InflaRx N.V.

Jan-08	InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation IFRX GlobeNewswire
Dec-30	InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum IFRX GlobeNewswire
Dec-11	InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 IFRX GlobeNewswire
Nov-10	InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) IFRX GlobeNewswire
Nov-07	InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria IFRX GlobeNewswire
Oct-21	InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference IFRX GlobeNewswire
Sep-12	InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement IFRX GlobeNewswire
Aug-21	InflaRx Announces Participation in September Investor Conferences IFRX GlobeNewswire
Aug-07	InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update IFRX GlobeNewswire
Jul-31	InflaRx to Report Second Quarter 2025 Results on August 7, 2025 IFRX GlobeNewswire
Jul-11	InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement IFRX GlobeNewswire
May-28	InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum IFRX GlobeNewswire
May-22	InflaRx to Participate in Upcoming Investor Conferences IFRX GlobeNewswire
May-07	InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update IFRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.